NEW YORK--(BUSINESS WIRE)---- $BKT--BlackRock Income Trust, Inc. (NYSE: BKT) (the "Fund†) announced today the renewal of its discount management program (the "Program"). Under terms of the Program, the Fund intends to offer to repurchase a portion of its common shares via tender offer if certain conditions are met, as detailed below. If the Fund's common shares trade at an average daily discount to net asset value ("NAV") of more than 7.50% during the 12-week measurement period beginning on July 9, 2026. ...

Core Viewpoint - Blue Water Acquisition Corp. III has decided to suspend its participation in the CITGO acquisition process due to misalignment with current market and regulatory conditions [1][2]. Company Overview - Blue Water Acquisition Corp. III (NASDAQ: BWAC) is a special purpose acquisition company focused on merging with businesses that utilize artificial intelligence, data science, and advanced technologies to transform energy, infrastructure, and industrial markets [3]. Market Insights - The CITGO acquisition process provided valuable insights into the U.S. energy infrastructure landscape, but the company concluded that the current conditions do not meet its immediate objectives [2]. Financial Position - Blue Water remains well-capitalized and is focused on pursuing high-impact opportunities across multiple sectors, indicating a strong financial foundation despite the suspension of the CITGO acquisition [2].

SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM), (the “Company”), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure, today announced its third quarter results for the period ended September 30, 2025. Recent Operational Highlights ●Opened Beam Middle East offices and entered the MEA market through a joint venture with the Platinum Group in Abu Dhabi ●Deployed EV ARC™ and ...

NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it intends to effect a one-for-nineteen reverse split (the "Reverse Stock Split") of the Company’s common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin trading on a ...

Core Insights - XWELL, Inc. reported third-quarter revenue of approximately $7.3 million for the period ending September 30, 2025, with significant improvements in cost management and operational efficiency [6][15] - The company is expanding its wellness services beyond airport locations, with new centers opening in Florida and New York City, enhancing accessibility for consumers [3][7][14] - XWELL has streamlined its corporate cost structure, reducing annualized staffing costs by approximately $2.4 million, and integrated its HyperPointe™ business to optimize resources [4][5] Recent Operating Highlights - The CEO emphasized progress in diversifying access points and enhancing brand relevance, particularly through partnerships like the expanded collaboration with Priority Pass [3] - New off-airport wellness centers have been opened, including locations in Penn Station, New York, and various Florida markets, aimed at serving local consumers [3][6][7] Financial Overview - Revenue breakdown for Q3 2025: approximately $5.1 million from XpresSpa, $1.7 million from XpresCheck, and $0.5 million from Naples Wax Center [15] - Cost of sales decreased by about 8% compared to the same quarter in 2024, while general and administrative expenses fell by approximately 32% [6][15] - The operating loss for the quarter was approximately $0.8 million, a significant reduction from the $4.8 million loss in the prior year [15] Strategic Initiatives - XWELL's partnership with Priority Pass has expanded to key international airports in the Middle East and Europe, enhancing traveler access to wellness offerings [6][7] - The company is leveraging its biosecurity program, XpresCheck, to capture growth opportunities in travel and mass-gathering settings, including major global events [8][9][10] Liquidity and Financial Condition - As of September 30, 2025, XWELL had approximately $4.0 million in cash and cash equivalents, with total current assets of about $10.8 million and no long-term debt [11]

Core Insights - PetVivo Holdings, Inc. reported a 51% increase in revenues for the second quarter of fiscal year 2026, totaling $303,000, driven by the introduction of the new product line PrecisePRP and expansion into the companion animal market [7][19][21] - The company has successfully entered the European market through a partnership with Nupsala Group, enhancing its distribution capabilities [6][16] - PetVivo's strategic collaborations, including with Digital Landia and Commonwealth Markets, are expected to enhance product adoption and market presence [10][17][18] Fiscal Q2 Financial Highlights - Revenues increased to $303,000, up 51% from the same quarter last year, marking a record for the second fiscal quarter [7][19] - Gross profit rose to $220,000, with a gross margin of 72.6%, an improvement from 63.8% in the previous quarter [20] - Operating loss increased to $2.1 million, while net loss rose to $3.0 million, reflecting increased sales and marketing expenses [21][22] Fiscal Q2 Operational Highlights - The company engaged additional distributors to support domestic and international expansion, with national distributor network sales increasing by 35% [7][19] - PetVivo's flagship product, Spryng with OsteoCushion Technology, has been adopted by over 1,200 veterinary clinics across the U.S. [17] - The company launched three new continuing education courses for veterinary professionals to enhance expertise in osteoarthritis and regenerative modalities [13] Strategic Partnerships and Innovations - A strategic partnership with Digital Landia aims to integrate AI technology into PetVivo's veterinary products, potentially reducing client acquisition costs significantly [10][18] - The collaboration with Commonwealth Markets has led to the integration of Spryng and PrecisePRP into care protocols for thoroughbred horses [17] - Ongoing research with PiezoBioMembrane is focused on developing biodegradable piezoelectric materials for regenerative applications [12][15] Financial Outlook - Management anticipates continued record growth for the full fiscal year ending March 31, 2026, driven by the expansion of Spryng and PrecisePRP [24][25] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [18]

Frontline plc (the “Company”) announces that its 2025 Annual General Meeting will be held on December 8, 2025. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F for 2024 can be found on our website at www.frontlineplc.cy and attached to this press release. November 14, 2025Limassol, Cyprus This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments FRO - Not ...

SINGAPORE, Nov. 15, 2025 (GLOBE NEWSWIRE) -- BGIN BLOCKCHAIN LIMITED (“BGIN” or the “Company”; NASDAQ: BGIN), a digital asset technology company with proprietary cryptocurrency mining technologies and an innovator in cryptocurrency mining hardware and infrastructure, today released its unaudited financial results for the six months ended June 30, 2025 (“1H 2025”). 1H 2025 Financial Highlights Total revenue was US$47.7 million, compared with US$144.5 million in the same period of 2024.Mining revenue increase ...

Tech stocks had their worst week since early April last week as Wall Street debated the existence of an AI bubble. Spencer Platt / Getty Images Close Key Takeaways Tech stocks have at times appeared unstoppable this year. Now they're in a rut. The tech-heavy Nasdaq Composite soared nearly 60% between April 8, when tariff uncertainty was at its highest, and Oct. 29, the index's most recent record high. Those gains were driven mostly by the AI trade, which encompasses a variety of stocks across the technology ...

Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2-2025. Patho ...